US Rheumatology Drugs Market Analysis Report 2022 to 2030

US Rheumatology Drugs Market Analysis

$ 3999

The US Rheumatology Drugs Market is projected to grow from $25.641 Bn in 2022 to $27.329 Bn by 2030, registering a CAGR of 0.8% during the forecast period of 2022-2030. The development of new biologic drugs, such as tumour necrosis factor (TNF) inhibitors, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors, has expanded the treatment options for rheumatic conditions, driving the market growth. Pfizer is one of the leading pharmaceutical companies in the world and offers a range of rheumatology drugs, including TNF inhibitors and JAK inhibitors.

ID: IN10USPH022 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Shivam Zalke

Buy Now

US Rheumatology Drugs Market Executive Summary

The US Rheumatology Drugs Market is projected to grow from $25.641 Bn in 2022 to $27.329 Bn by 2030, registering a CAGR of 0.8% during the forecast period of 2022-30.

The US rheumatology drugs market is a lucrative market, driven by a growing aging population, increasing prevalence of chronic conditions such as rheumatoid arthritis, and the development of new, biologic drugs. The market is dominated by a few key players, including Pfizer, Johnson & Johnson, and Roche. These companies offer a range of traditional small molecule drugs and biologic drugs, such as tumor necrosis factor (TNF) inhibitors, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors. The market is expected to continue growing, driven by the increasing incidence of rheumatic diseases, as well as the development of new, innovative treatments.

Rheumatology is a medical specialty that deals with the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are a group of conditions that affect the joints, bones, and muscles, and can cause pain, stiffness, and swelling. Examples of rheumatic diseases include rheumatoid arthritis, osteoarthritis, lupus, and gout.

In the US, rheumatology is a rapidly growing field, driven by an aging population and increasing prevalence of chronic conditions such as rheumatoid arthritis. Rheumatologists are specialized medical doctors who diagnose and treat rheumatic diseases using a range of treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic drugs.

US rheumatology drugs market analysis

Market Dynamics

Market Drivers

The key drivers of the US rheumatology drugs market are:

Growing aging population: The aging population is more susceptible to chronic conditions such as rheumatoid arthritis, leading to an increase in demand for rheumatology drugs
Increasing prevalence of chronic rheumatic conditions: The prevalence of chronic rheumatic conditions such as rheumatoid arthritis and osteoarthritis is increasing, driving demand for effective treatments
Development of new, innovative drugs: The development of new biologic drugs, such as tumor necrosis factor (TNF) inhibitors, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors, has expanded the treatment options for rheumatic conditions, driving the market growth
Rising healthcare expenditure: The rising healthcare expenditure in the US is expected to lead to increased spending on rheumatology drugs, further driving the market growth
Government support for healthcare: Government support for healthcare, including funding for research and development, is expected to boost the growth of the rheumatology drugs market

Competitive Landscape

Key Players

The key players in the US rheumatology drugs market are:

Pfizer Inc.: Pfizer is one of the leading pharmaceutical companies in the world and offers a range of rheumatology drugs, including TNF inhibitors and JAK inhibitors
Johnson & Johnson: Johnson & Johnson is a global healthcare company that offers a range of rheumatology drugs, including TNF inhibitors and IL-6 inhibitors
Roche: Roche is a Swiss multinational healthcare company that offers a range of rheumatology drugs, including TNF inhibitors and IL-6 inhibitors
AbbVie: AbbVie is a biopharmaceutical company that offers a range of rheumatology drugs, including TNF inhibitors and JAK inhibitors
Amgen: Amgen is a biopharmaceutical company that offers a range of rheumatology drugs, including TNF inhibitors and IL-6 inhibitors

These companies dominate the US rheumatology drugs market and offer a range of traditional small molecule drugs and biologic drugs to treat rheumatic conditions. They invest heavily in research and development to expand their product portfolios and remain competitive in the market.

Healthcare Policies and Regulatory Landscape

The US rheumatology drugs market is heavily influenced by healthcare policies and regulations. The following are some of the key policies and regulations that impact the market:

FDA Approval: The US Food and Drug Administration (FDA) is responsible for evaluating and approving new drugs for the treatment of rheumatic conditions. The approval process can be lengthy and costly, and companies must demonstrate the safety and efficacy of their drugs before they can be marketed.
Reimbursement: Reimbursement policies play a critical role in the uptake of rheumatology drugs, as patients must be able to afford these treatments. The Centers for Medicare & Medicaid Services (CMS) determines the reimbursement rates for drugs covered under Medicare and Medicaid, and private insurance companies also have their own reimbursement policies.
Intellectual Property Rights: Intellectual property rights, including patents, play a significant role in the development of new rheumatology drugs. Companies rely on patents to protect their innovations and prevent others from producing generic versions of their drugs.
Price Control: The US government has implemented various price control measures to control the cost of drugs, including negotiating prices with drug manufacturers and limiting the prices of drugs covered under Medicare and Medicaid.

These policies and regulations play a crucial role in shaping the US rheumatology drugs market and impact the development, approval, and marketing of new drugs. Companies must navigate this complex landscape to bring new treatments to market and remain competitive in the market.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Rheumatology Drug Market Segmentation

Drug Class

The disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost the growth of the segment.

Disease-modifying anti-rheumatic drugs (DMARDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Uric acids
Others

Route of administration

Oral
Parental

Sales channel

Depending on the sales channel, the prescription-based drug segment is the major shareholder in the US rheumatoid drugs market, owing to the advantages offered by prescription-based drugs.

Prescription-based drugs
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.